Abstract
Background We investigated whether stroke volume reserve (STVR) would predict 1-year mortality and need for advanced therapies in heart-failure with reduced ejection fraction (HFrEF) patients.
Methods and Results We retrospectively studied 104 ambulatory patients with HFrEF (59.2±10.2 years, 89% male) referred for cardiopulmonary exercise testing (CPET). At 1 year, 39 outcomes were observed: 16 heart-transplants (HTx), 8 left ventricular assist devices (LVAD), and 15 deaths. Stroke volume (SV) was determined by the Fick principle with established values for C[a-v]O2 at rest and anaerobic threshold (AT). STVR was calculated by SVAT/SVrest. Multi-predictor regression showed a correlation of STVR≤1.3 (OR 7.92, p=0.002), cardiac index by right heart catheterization≤2 (OR 3.07, p=0.049), and peak VO2 below the 2016 ISHLT cut-off (OR 4.09, p=0.011). HFrEF patients with a low peak VO2 and STVR>1.3 showed similar survival compared to patients with a peak VO2 above the ISHLT cut-off. A scoring system was developed: STVR≤1.3—2 points, peak VO2 below the ISHLT cut-off—1 point, and cardiac index≤2—1 point. A score of ≥3 demonstrated a sensitivity of 67% and specificity of 79% for 1-year events.
Conclusions STVR is a novel parameter that may better predict 1-year outcomes than peak VO2 in HFrEF patients.
Highlights
Peak VO2 is used to predict outcomes in HFrEF patients.
Peak VO2 correlates poorly with mortality due to many contributing factors.
STVR is a novel CPET parameter that may better predict outcomes than peak VO2.
Patients with adequate peak VO2 but abnormal STVR are at high risk for 1-year events.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors did not receive any payment or services related to this research project
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data referred to in the manuscript is available and can be obtained by emailing iselevany{at}health.ucsd.edu
